LITHIOPATHIES

Towards gene identification and personalized prophylactic medication for lithiopathies in lithium-using patients

Coordinatore	STICHTING KATHOLIEKE UNIVERSITEIT    more  Organization address address: GEERT GROOTEPLEIN NOORD 9 city: NIJMEGEN postcode: 6525 EZ contact info Titolo: Mr. Nome: Maarten Cognome: Van Langen Email: send email Telefono: +31 243619791
Nazionalità Coordinatore	Netherlands [NL]
Totale costo	270˙786 €
EC contributo	270˙786 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2012-IOF
Funding Scheme	MC-IOF
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-05-01   -   2017-04-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	STICHTING KATHOLIEKE UNIVERSITEIT  Organization address address: GEERT GROOTEPLEIN NOORD 9 city: NIJMEGEN postcode: 6525 EZ contact info Titolo: Mr. Nome: Maarten Cognome: Van Langen Email: send email Telefono: +31 243619791	NL (NIJMEGEN)	coordinator	270˙786.30

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Lithium is widely prescribed and the mainstay treatment for bipolar disorders. Unfortunately, lithium treatment often leads to adverse side effects (lithiopathies) like hypercalcaemia, nephrogenic diabetes insipidus and chronic kidney disease.

Despite the above lithiopathies, cessation of lithium therapy is not an option for most patients, because there is no good alternative and the bipolar disorder has a larger impact on the patient’s quality of life. However, rationally-based medication for lithiopathies exists. As the lithiopathies are largely irreversible, the medication should be administered with the start of lithium treatment. However, prophylactic administration of these medications to lithium-using patients is undesirable, because not all patients develop lithiopathies. Therefore, to target for lithiopathy-specific personalized prophylactic medication for lithium-using patients, the aim of this study is to identify the susceptibility genes for development of the lithiopathies.

To identify these susceptibility genes I propose to employ state-of-the-art haplotype association mapping (HAM) with mice at a world-recognized expertise centre for genetic research. As the used inbred mouse strains are fully genotyped, produce genetically identical offspring, and develop the lithiopathies consistently and on short term, HAM has clear benefits over genome-wide association studies in humans. At the return host, the role of identified susceptibility genes will be confirmed in cell and animal lithiopathy models and the corresponding orthologous genes in lithium-using patients will be tested for association with the lithiopathies. The project will not only provide the first steps towards personalized prophylactic medication for lithium users, but is also the perfect setup for a future scientific career of the applicant.'